SCHEMBL23928217

SCHEMBL23928217

CN1CCC(C(=O)Nc2ccc(CCN)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.55
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
LMNA P02545 2/20 0.54
GAA P10253 1/20 0.53
TSHR P16473 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
PKM P14618 1/20 0.52
TP53 P04637 1/20 0.50
MAPT P10636 1/20 0.50
CARM1 Q86X55 1/20 0.48
PRMT6 Q96LA8 1/20 0.48
NAMPT P43490 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
PTPN1 P18031 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP2C19 P33261 1/20 0.47
GLA P06280 1/20 0.47
PARP1 P09874 1/20 0.47
CTNNB1 P35222 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23963156 0.92 PKM (0.63) POLBMEN1KMT2ALMNAGAA
SCHEMBL10306612 0.85 POLB (0.74) POLBMEN1KMT2ALMNAGAA
SCHEMBL23928125 0.83 POLB (0.52) POLBMEN1KMT2ALMNAGAA
SCHEMBL7399741 0.80 F10 (0.63) LMNATP53MAPTGLA
SCHEMBL15522577 0.80 POLB (0.55) POLBMEN1KMT2ALMNAGAA
SCHEMBL15522519 0.80 SMN1; SMN2 (0.57) POLBMEN1KMT2ALMNAGAA
SCHEMBL19302972 0.80 ALDH1A1 (0.69) POLBGAATSHRPKMMAPT
Hydrochloric Acid SCHEMBL15522456 0.79 POLB (0.54) POLBMEN1KMT2ALMNAGAA
SCHEMBL23291304 0.79 MEN1 (0.51) POLBMEN1KMT2ALMNAGAA
SCHEMBL10131252 0.79 LMNA (0.60) POLBMEN1KMT2ALMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814356-B1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) 2026-03-11 EP disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 US disclosed
CN-111051309-B Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2023-05-26 CN disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2021-10-28 US disclosed
CN-111051309-A Triazolotriazine derivatives useful as A2A receptor antagonists 浙江春禾医药科技有限公司 2020-04-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 POLB 4559/4885MEN1 1329/4885KMT2A 1530/4885
US-20210332055-A1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ADORA2A, ADORA1, ADORA3 POLB 4559/4885MEN1 1329/4885KMT2A 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.